Strategic License Agreements (Details) $ in Thousands		1 Months Ended		12 Months Ended
	Sep. 26, 2019 USD ($) institution	Dec. 31, 2020 USD ($)	Oct. 31, 2014 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent consideration, payment				$ (8,600)	$ (5,600)	$ (1,300)
Business consideration liabilities		$ 42,400		42,400	63,800
Number of research institutions party to license agreement | institution	2
Research and development expense				10,700	251,437	$ 0
Tevard Biosciences
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Option agreement, amount paid				5,500	$ 2,000
Collaboration agreement consideration		5,200		5,200
Promissory notes purchased		$ 5,000		5,000
Advance notice needed		180 days
Collaboration agreement, upfront payment		$ 10,200		10,200
In progress research and development		$ 5,200		5,200
Research and development expense				$ 700
Tevard Biosciences | Convertible Note Receivable
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Interest rate (percent)		3.50%		3.50%
Tevard Biosciences | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Additional milestone payments		$ 100,000		$ 100,000
Modis Acquisition
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expiration period of license agreement following first bona fide sale of licensed product	15 years
Upon Achievement of Regulatory Milestones | Modis Acquisition | Columbia University
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent payment under license agreement	$ 2,900
Upon Achievement of Certain Commercial Milestone Events | Modis Acquisition
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent payment under license agreement	10,000
Upon Achievement of Certain Commercial Milestone Events | Modis Acquisition | Columbia University
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent payment under license agreement	25,000
Upon Achievement of Research, Development and Regulatory Milestone | Modis Acquisition
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent payment under license agreement	$ 3,000
Brabant Pharma Limited
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Aggregate amount of contingent liabilities			$ 95,000
Business consideration liabilities		42,400		42,400
Brabant Pharma Limited | Regulatory Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Aggregate amount of contingent liabilities			50,000
Contingent consideration, payment			35,000
Business consideration liabilities		$ 15,000		$ 15,000
Brabant Pharma Limited | Sales Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Aggregate amount of contingent liabilities			$ 45,000